TOP HEADLINES

Featured Story

Sanofi leads $11M Series A round for needle-free delivery company

Portal Instruments, a new Boston-based company, secured $11 million for its computerized needle-free drug delivery system via a Series A funding round led by Sanofi, Boston-based VC PBJ Capital and a major medical device company. It became only the third company to receive funding under Sanofi's Sunrise Initiative for early stage companies.

GSK exec stresses need to move away from 'fragmented' approach to drug delivery

Talking of breaking internal siloes has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKlines' head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference.

Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients

At the American Neurological Association's 2014 Annual Meeting in Baltimore, Alnylam released 6-month data on its Phase 2 open-label extension (OLE) study of patisiran (ALN-TTR02), a clinical-stage RNAi candidate for the treatment of TTR-mediated amyloidosis in patients with familial amyloidotic polyneuropathy.

Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads

Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.

Stem cell-derived beta cells deliver insulin in response to blood sugar levels

The self-regulation of insulin delivery is a long-sought goal in the field, spurring the development of closed-loop systems and an artificial pancreas for diabetics. But some researchers are aiming smaller, looking at a way to create stem cells en masse that can produce insulin in response to blood sugar levels.

MORE NEWS

From Our Sister Sites

FiercePharmaMarketing

Brace yourselves for layoffs at GlaxoSmithKline. The saga is familiar: An aging blockbuster loses steam to competing meds, and its maker gets out the cost-cutting ax to compensate. This time, the...

FierceMedicalDevices

Cardiovascular device company Sorin Group has invested $20 million in Respicardia. The financing is to be used to fund ongoing clinical testing of the startup's remede System, which is a pacemaker-like device for central sleep apnea that delivers electrical pulses via an implantable lead to the phrenic nerve.